![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/preliminary-clinical-data-on-relma-cel-injection-in-adults-with-active-systemic-lupus-erythematosus-in-china-at-the-eular-2024-congress-302159238.html
https://www.prnewswire.com/news-releases/jw-therapeutics-announces-ind-approval-for-the-clinical-trial-of-relma-cel-in-patients-with-moderately-or-severely-refractory-systemic-lupus-erythematosus-301793059.html
https://www.prnewswire.com/news-releases/jw-therapeutics-announces-its-cell-immunotherapy-drugs-have-successfully-benefited-406-patients-301784761.html
https://www.prnewswire.com/news-releases/jw-therapeutics-announces-initiation-of-clinical-study-of-carteyva-in-first-line-treatment-in-patients-with-high-risk-large-b-cell-lymphoma-301763117.html
https://www.prnewswire.com/news-releases/jw-therapeutics-announces-initiation-of-clinical-study-of-jwatm214-in-patients-with-advanced-hepatocellular-carcinoma-301752957.html
https://www.prnewswire.com/news-releases/jw-therapeutics-presents-latest-clinical-data-on-carteyva-in-follicular-lymphoma-and-mantle-cell-lymphoma-at-the-64th-ash-annual-meeting-301698981.html
https://www.pharmaceutical-technology.com/news/2seventy-jw-therapeutics-immunotherapies/
https://www.prnewswire.com/news-releases/jw-therapeutics-announces-nmpa-approval-of-relmacabtagene-autoleucel-injection-in-patients-with-relapsed-or-refractory-follicular-lymphoma-301644493.html
https://www.asiaone.com/business/jw-therapeutics-announces-initiation-clinical-study-jwatm204-patients-advanced